European regulators fortify single-arm trial advice, but underscore preference for placebo-controlled designs

The Eu­ro­pean Med­i­cines Agency has so­lid­i­fied its rec­om­men­da­tions to drug­mak­ers that want to use sin­gle-arm de­signs in a piv­otal tri­al, but em­pha­sized that any such …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.